Business
Appointment of Chief Commercial Officer
Appointment of Chief Commercial Officer.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 1036Y Faron Pharmaceuticals Oy 01 December 2017 \n\nFaron Pharmaceuticals Oy\n(\"Faron\" or the \"Company\")\n \nAppointment of Chief Commercial Officer\n \nDr. Juhana Heinonen, previously AstraZeneca's Global Marketing Director, to steer commercialisation strategy for Faron's lead candidate Traumakine \n \nTURKU - FINLAND, 01 December 2017 - Faron Pharmaceuticals Oy (\"Faron\" or \"Company\") (LON: FARN), the clinical stage biopharmaceutical company, is pleased to announce the appointment of Dr. Juhana Heinonen as Chief Commercial Officer to join the Company in January 2018. \n \nDr Heinonen joins Faron from AstraZeneca where he served as the Global Marketing Director for AstraZeneca/Medimmune's Fasenra (benralizumab) for the treatment of asthma, the first biologic medication launched from the AstraZeneca respiratory unit. Dr Heinonen led global market shaping and patient and healthcare professional support strategy development for the new monoclonal antibody, which met the primary endpoints in two Phase III clinical trials in 2016. Prior to this, he held a variety of positions in sales and marketing at Roche between 2008 and 2015, successfully leading the launch and development of a global marketing strategy for the blockbuster treatment for rheumatoid arthritis, RoACTEMRA (tocilizumab).\n \nAt Faron, Dr Heinonen will be directly responsible for the development and execution of a pre-launch and launch commercialisation strategy for Faron's wholly-owned lead candidate, Traumakine. Traumakine is currently in late stage Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS). This work will pave the way for Traumakine to enter markets post approval of European MAA and US BLA.\n \nCommenting on the CCO's appointment, Dr Markku Jalkanen, CEO of Faron, said:\n\"I am delighted to announce the appointment of Juhana to the new role of Chief Commercial Officer. He has a wealth of expertise in the commercialisation and marketing of blockbuster drugs, and will be a key addition to the Faron team as we continue our preparations to enter commercialisation. We look forward to benefitting from his experience and valuable insights as our wholly-owned lead product, Traumakine, approaches the completion of its pivotal Phase III ...